

# 57th OOG Meeting in Berlin/Germany 2023

April 13-16



**Thursday, 13<sup>th</sup>**

11.00-12.00 Registration at Kaserin Friedrich Stiftung

**For access to the Helmholtz Zentrum: Full name, City, Country, Number of ID of all attendees id is required! Please bring passport.**

12:00 Departure Bus to Helmholtz Zentrum for Proton beam therapy

12.45-13.00 small **lunch** provided

## Welcome

13.00-13.10 Welcome Prof Dr Joussem (host) / Dr Moulin (president OOG)

13.10-13.20 Welcome Prof. Andrea Denker (Proton beam Facility)



## YIN meeting

### Welcome

13.20-13.30 Welcome Mr. Malaise / Mrs. Nguyen (YIN representatives)

### Physics in Ocular Oncology invited speakers

Chairs: Malaise / Nguyen

13.30-13.50 Jan Willem Beenakker (Leiden, NL)  
Advances in MRI of intra-ocular lesions

13.50-14.10 Jens Heufelder (Berlin, D)  
Radiotherapy of intraocular tumors: present and future

14.10-14.30 Linda Mortimer (Clatterbridge, GB)  
Ocular proton therapy worldwide results of the PTCOG OPTIC  
questionnaire

### Experimental approaches

Chair: van Poppelen

14.30-14.45 Susanne Wolf (Berlin, D)  
Organoids in Uveal melanoma research

14.45-15.00 Marie Laure Yaspo  
Comprehensive profiling benefits

15.00-15:30 **Break**

## 57th OOG Meeting



### **Presentations Imaging and Irradiation** submitted abstracts

Chairs: Beenakker / Eiger-Moscovich

- 15.30-15.40 Klaassen  
Quantitative analysis of perfusion-weighted magnetic resonance imaging in uveal melanoma
- 15.40-15.50 Gollrad  
Advantages of 3-D image-based versus conventional model-based treatment planning in ocular proton therapy
- 15.50-16.00 Mularska  
A-OCT in early recognition of radiation retinopathy – a pilot study
- 16.00-16.10 Midená  
Radiation Maculopathy: an Imaging and Omic Combined Diagnostic Approach
- 16.10-16.20 Eiger-Moscovich  
Baseline MRI screening for bilateral retinoblastoma patients
- 16.20-16.30 Weber  
Advantages of Helium Ion beams in particle therapy of ocular tumors
- 16.30-16.40 Denker  
Status and Perspectives for the Treatment of Intra Ocular Tumors with Protons and Helium Ions – enabling ocular FLASH particle therapy
- 16.40-16.50 Strauß  
From mice to man: in vivo analysis of retinal function in animal models for retinal disease and its translational value
- 16.50-18.00 **Tour of the proton beam therapy center**
- 19.00 **Dinner**
- 20:30 Bus back to Berlin

## Friday 14<sup>th</sup>

### Uveal melanoma Genetics (invited speakers)

Chair: Pfeffer

- 9.00-9.20 Emine Kilic (Rotterdam, NL)  
Which are the important players in genetics?
- 9.20-9.40 Jens Folke Kiilgaard (Copenhagen, DK)  
Is there progress in malignancy from small uveal melanoma to large melanoma to metastasis?
- 9:40-10.00 Natasha van Poppelen (Rotterdam, NL)  
Genetics of ocular melanoma and non-malignant lesions

### Uveal melanoma presentations 1<sup>st</sup> round (submitted abstracts)

Chairs: Kiilgaard / Damato

- 10.00-10.10 Hindso  
Validation of AJCC staging for metastatic disease in a Danish cohort of patients with metastases from posterior uveal melanoma
- 10.10-10.20 Negretti  
Iris melanoma outcomes based on The Cancer Genome Atlas (TCGA) classification in 78 consecutive patients
- 10.20-10.30 Schröder  
Uveal Melanoma App – current expert knowledge in digital form
- 10.30-10.40 Rosnev  
Survival of uveal melanoma patients with peritoneal metastases: a retrospective single-center analysis
- 10.40-10.50 Rospond-Kubiak  
The extraocular extension of the uveal melanoma
- 10.50-11.00 Lanza  
Large optic disc melanocytoma: a long-term follow-up case series
- 11.00-11.30 **Break**

### Uveal melanoma presentations 2<sup>nd</sup> round (submitted abstracts)

Chairs: Rosnev / Rospond-Kubiak

- 11.30-11.40 Amaro  
Interdependence of molecular lesions that drive Uveal Melanoma metastasis
- 11.40-11.50 Kreidieh  
Atypical outcomes from uveal melanoma tumors with Class 1A, 1B, and 2 gene expression profiles
- 11.50-12.00 Tura  
Hyperglycemia-induced missegregation of chromosome-3 in the uveal melanoma cells

- 12.00-12.10 Le Guin  
Detection of ctDNA in vitreous body and aqueous humor of uveal melanoma patients
- 12.10-12.20 Grishina  
Cell free DNA as a prognostic marker for early metastasis of uveal melanoma
- 12.20-12.30 Reggiani  
Application of multi-domain genomic data integration for Uveal and Skin Melanoma
- 12.30-12.40 Brosens  
Whole genome, methylation and transcriptome sequencing of primary Uveal melanoma

### **Uveal melanoma Metastasis – Prevention**

Chair: Vishnevskia-Dai

- 12.40-13.00 Ulrich Keilholz (Belin , D)  
System Medicine in Choroidal melanoma

13.00-14.00 **Lunch**

14.00-15.00 **Collaborative initiatives** open discussion

Chair: Moulin/ Leyvraz

Request to all OOG members to mail collaborative proposals to the secretary [r.verdijk@erasmusmc.nl](mailto:r.verdijk@erasmusmc.nl)

### **Uveal melanoma presentations 3<sup>rd</sup> round** (submitted abstracts)

Chairs: Bornfeld / Heufelder

- 15.00-15.10 Manke  
A novel integrated concept to treat large intraocular tumors
- 15.10-15.20 Vishnevskia-Dai  
Iodine -125 Plaque Radiotherapy for Choroidal Melanoma. Treatment Results, treatment related complications, Ocular and Systemic Prognosis
- 15.20-15.30 Krema  
Deep-notch Episcleral Iodine-125 plaque for the treatment of juxtapapillary melanoma
- 15.30-15.40 Quhill  
Melanoma Recurrence or Something Else?
- 15.40-15.50 Zwolinska  
Ruthenium brachytherapy for iridocilliary melanoma
- 15.50-16.00 Angi  
Uveal melanoma treatment with active scanning beam protontherapy: the CNAO/INT experience

16.00-16.30 **Break**

**Uveal melanoma presentations 4<sup>th</sup> round** (submitted abstracts)

Chairs: Kilic / Joussem

16.30-16.40 Fermon

Endoresection of choroidal melanoma after proton beam irradiation: a retrospective interventional case series

16.40-16.50 Böker

Review of 166 patients with iris melanoma treated proton beam therapy

16.50-17.00 Foerster

Robotic CyberKnife Radiosurgery for the Treatment of Uveal Melanoma

17.00-17.10 Demirci

A Phase 2 Trial of Belzupacap Sarotalocan (Bel-sar), a First-in-Class Targeted Therapy for Choroidal Melanoma, via Suprachoroidal Administration

17.10-17.20 Patel

How to make strawberry ice cream: two types of cell therapy trials in uveal melanoma

17.20-17.30 Grisanti

Detection of Circulating Tumor Cells in Small Choroidal Melanocytic Lesions

17.30-17.40 Tonelotto

Identifying Uveal Melanoma Biomarkers from Patient Extracellular Vesicles and the Pharmacological Action of 1,4 Dihydroxy Quininib

17.40-17.50 Kennedy

Ergolide Mediates Anti-Cancer Effects on Metastatic Uveal Melanoma Cells and Modulates their Extracellular Vesicle Proteome

18.00 departure on foot for Ship cruise

18.45 **Ship cruise with Dinner**

## **Saturday 15<sup>th</sup>**

### **9.00-10.00 OOG Business Meeting**

Chairs: OOG board

### **Orbit Anterior Segment Tumors** (invited speaker)

Chair: Moulin

10.00-10.20 Bertelmann

Different surgical approaches to the orbit are currently in clinical use.  
There is limited clinical data on comparison of the different options

### **Orbit and ocular adnexa** (submitted abstracts)

Chairs: Briscoe / Tunc

10.20-10.30 Wu

Global Trends in Incidence of Ocular Melanoma and Iris Color  
Prevalence

10.30-10.40 van Ipenburg

ATRX loss in (pre-) malignant melanocytic lesions of the conjunctiva

10.40-10.50 Frenkel

Treatment of Conjunctival Palpebral Tumors Using Ruthenium Plaque  
Brachytherapy

10.50-11.00 Keersmaecker

Malignant tumors of the eyelid and the eye surface: one-time frozen  
section procedure or two-time procedure

11.00-11.10 Gutmann

Epidemiological characteristics and clinical outcome of facial Merkel  
cell carcinoma

11.10-11.20 Savino

Post-operative Interventional Radiotherapy (Brachytherapy) in  
advanced eye and eyelid tumors as alternative treatment to invasive  
surgery

11.20-11.30 Alfaar

The characteristics of childhood ocular and orbital malignancies in the  
USA, 1996-2018

11.30-11.40 Briscoe

Combining Nasal Endoscopic & Anterior Orbitotomy Approach in the  
Orbital Apex

11.40-11.50 Koca

Novel characteristics of Orbital Solitary Fibrous Tumour: Prevalence of  
TERT-promotor mutation and radiographic properties in multimodal  
imaging

11.50-12.00 Verdijk

Two cases of intra-ocular undifferentiated pleomorphic sarcoma

12.00-12.10 Kindler  
Ocular Oncology - Problems and Solutions in Animals

12.10-13.00 **Lunch**

**Lymphoma** (invited speaker)

Chair: Verdijk

13.00-13.20 Bahram Bodhagi (Paris, F)  
The ophthalmologists View

**Retina** (submitted abstracts)

Chairs: Matet / Zeitz

- 13.20-13.30 Matet  
Molecular exploration of aqueous humor cfDNA in retinoblastoma
- 13.30-13.40 Moulin  
Retinal giant cell astrocytoma: report of 2 cases
- 13.40-13.50 Faber  
Primary vitreoretinal lymphoma in the capital region of Denmark.  
Clinical features and treatment outcomes
- 13.50-14.00 Murtagh  
Primary Vitreoretinal Lymphoma: Examining patient outcomes based  
on varying diagnostic and treatment modalities
- 14.00-14.10 Rudolph  
Correlation of a preoperative priority list with the final diagnosis of  
primary vitreoretinal lymphoma (PVRL)
- 14.10-14.20 Rating  
IL-10/IL-6 ratio in the diagnosis of intraocular lymphoma
- 14.20-14.30 Tunc  
To analyse clinical outcome of Cyberknife SRT in a series of patients  
with Choroidal hemangioma
- 14.30-14.40 Nissen  
Outcome of combined cataract surgery and iris prosthesis implantation  
in patients with previous iris melanoma surgery
- 14.40-14.50 Pagliara  
Exudative retinal detachment in uveal melanomas treated with  
interventional radiotherapy
- 14.50-15.00 Zeitz  
Outcome optimization after irradiation of ocular tumors
- 15.00-15.10 Parrozzani  
Choroidal Vascular Changes Secondary to Ocular Irradiation Because  
of Posterior UM
- 15.10-15.20 Malaise  
In vivo preclinical model of radiation retinopathy



15.30-16.00 **Break**

16:00-17:00 **Rapid fire session** (2 min presentation, 1 min questions each)

Chairs: Verdijk / Joussem

- |          |   |
|----------|---|
| Tura     | Influence of the stereotactic irradiation technique and monosomy-3 status on the extent of DNA damage in uveal melanoma   |
| Kennedy  | Prognostic significance of Bap1 protein expression in uveal melanoma  |
| Quhill   | Choroidal biopsy success by technique: the role of transscleral Essen forceps biopsy  |
| Alfaar   | The epidemiology of adults' ocular malignancies in Germany in a decade  |
| Alfaar   | The characteristics of adult ocular and orbital malignancies in the USA, 1996-2018  |
| Echieh   | Presentation of a recurrent conjunctiva cyst, a case report and review of literature  |
| Accetta  | Orbital metastasis of a neuroendocrine tumor  |
| Borselli | Our Experience in The Management of Uveal Metastasis Based on Rare Primary Tumor Origins: A Case Series   |
| Bonsen   | Everolimus in Tuberous Sclerosis Complex Patients with Retinal Hamartomas   |
| Borselli | Efficacy of Ultra-Low-Dose Radiotherapy in Association with Single-Agent Rituximab Compared with Standard External Radiotherapy Alone in Low Grade Orbital Lymphoma |
| Gollrad  | Radiation-induced changes to the anterior segment of mice eye   |
| Quhill   | Rise of an unexpected foe: secondary extraocular extension following photodynamic therapy   |
| Tunc     | Cyberknife Stereotactic Surgery for Vasoactive Proliferative Tumor of the Retina  |

17.00-19.00 **Walking tour:** Meet Albrecht von Graefe and Rudolf Virchow

19.00 **Dinner**

## Sunday 16<sup>th</sup>

### Social program:

10.00-13.00

- Reichstag w. guided tour  
or
- Nofretete → <https://www.museumsportal-berlin.de/de/museen/neues-museum/>  
or
- Jewish Museum Berlin → <https://www.jmberlin.de/>